分子分型对乳腺癌新辅助化疗后肿瘤退缩模式的影响

徐乘骏; 张朝蓬; 邱恒; 毕钊; 王永胜

doi:10.3969/j.issn.1000-8179.2018.17.351

分子分型对乳腺癌新辅助化疗后肿瘤退缩模式的影响

doi: 10.3969/j.issn.1000-8179.2018.17.351

徐乘骏^{①, ②,},
张朝蓬^②,
邱恒^{①, ②},
毕钊^{①, ②},
王永胜^②, ,

①.
济南大学山东省医学科学院医学与生命科学学院（济南市250200）
②.
山东大学附属山东省肿瘤医院乳腺病中心外科三病区（济南市250200）

详细信息

作者简介:
徐乘骏专业方向为乳腺癌的新辅助化疗，乳腺肿瘤的退缩模式研究等。E-mail：1240340577@qq.com

通讯作者:
王永胜 wangysh2008@aliyun.com

计量
- 文章访问数: 71
- HTML全文浏览量: 0
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-04
- 修回日期: 2018-09-11
- 刊出日期: 2018-09-15

Effect of molecular typing on breast tumor regression mode after neoadjuvant chemotherapy

Xu Chengjun^{①, ②
,},
Zhang Zhaopeng^②,
Qiu Heng^{①, ②},
Bi Zhao^{①, ②},
Wang Yongsheng^{②
, ,}

①.
School of Medicine and Life Sciences, University of Jinan and Shandong Academy of Medical Sciences, Jinan 250200, China
②.
Breast Cancer Center, Surgical Ward 3 (Breast Surgery), Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250200

More Information

Corresponding author: Yongsheng Wang; Email: wangysh2008@aliyun.com

摘要

摘要: 目的探讨乳腺癌新辅助化疗（neoadjuvant chemotherapy，NAC）后不同分子分型的乳腺原发病灶退缩模式。方法选取2008年7月至2017年10月山东大学附属山东省肿瘤医院收治的108例ⅡA~ⅢC期乳腺浸润性导管癌行新辅助化疗后手术患者的临床病理资料，手术标本制作次连续病理大切片，电子显微镜下勾画残余肿瘤范围，三维重建残余肿瘤，评价新辅助化疗后原发肿瘤临床病理退缩模式。结果 108例患者新辅助化疗后向心性退缩（concentric shrinkage mode，CSM）与非向心性退缩（nonconcentric shrinkage mode，NCSM）中Luminal A型分别占47.4%（9/19）与52.6%（10/19），Luminal B HER-2阴性型、HER-2阳性型分别占53.6%（15/28）、72.7%（16/22）与46.4%（13/28）、27.3%（6/22），HER-2阳性型分别占84.6%（11/13）与15.4%（2/13），三阴性乳腺癌分别占80.8%（21/26）与19.2%（5/26）。结论 Luminal B HER-2阳性型、HER-2阳性型及三阴性乳腺癌的原发肿瘤更易出现CSM，Luminal A型、Luminal B型HER-2阴性型的原发肿瘤临床病理退缩模式无显著性差异。分子分型可用于预测乳腺癌新辅助化疗后原发肿瘤的临床病理退缩模式，有助于选择新辅助化疗后适合保乳治疗的患者、降低局部复发率。
- 乳腺肿瘤 /
- 新辅助化疗 /
- 分子分型 /
- 退缩模式
Abstract: Objective To investigate the differences in shrinkage mode of the primary tumor in patients with different molecular subtypes of breast cancer after neoadjuvant chemotherapy (NAC). Methods One hundred and eight patients with breast invasive ductal carcinoma received NAC from July 2008 to October 2017 at Shandong Cancer Hospital Affiliated to Shandong University. After surgery, the surgical specimens were used to generate large continuous pathological sections. Using electron microscopy, the residual tumor range was delineated, residual tumor was reconstructed in three dimensions, and pathological regression pattern of the primary tumor after NAC was evaluated. Result Luminal A type accounted for 47.4% (9/19) and 52.6% (10/19) of patients with concentric shrinkage mode (CSM) and non-CSM (NCSM) after NAC, respectively. Luminal B human epidermal growth factor receptor 2 (HER2)+ type and HER2+ type accounted for 53.6% (15/28) and 72.7% (16/22) and 46.4% (13/28) and 27.3% (6/22) of patients, respectively. HER2+type accounted for 84.6% (11/13) and 15.4% (2/13) of patients, respectively, and triple-negative breast cancer accounted for 80.8% (21/26) and 19.2% (5/26) of patients, respectively. Conclusions Luminal B HER2+, HER2+, and basal-like types were more likely to have concentric shrinkage mode. The luminal A and luminal B HER2- type had no significant difference in primary tumor regression patterns. Molecular typing is helpful for predicting the regression mode of primary tumors after NAC in patients with breast cancer, which facifitates the selection of appropriate patients for breast-conserving therapy and redution of the local recurrence rate after NAC.
- breast tumor /
- neoadjuvant chemotherapy /
- molecular typing /
- shrinkage mode

HTML全文

表 1 108例乳腺癌患者临床病理退缩模式与患者肿瘤的临床病理特征

表 2 NAC后病理退缩模式评价结果

表 3 NAC后临床病理退缩模式评价结果

参考文献(14)

[1]	Hayes DF, Schott AF. Neoadjuvant chemotherapy: what are the benefits for the patient and for the investigator[J]? J Natl Cancer Inst Monogr, 2015, 2015(51):36-39. http://europepmc.org/abstract/MED/26063884
[2]	Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemothery in stage Ⅱ–Ⅲ triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB40603(Alliance)[J]. Ann Surg, 2015, 262 (3): 434-439. doi: 10.1097/SLA.0000000000001417
[3]	Ishitobi M, Ohsumi S, Inaji H, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast- conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index[J]. Cancer, 2012, 118(18):4385-4393. doi: 10.1002/cncr.27377
[4]	Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol, 2015, 26(8):1533-1546. doi: 10.1093/annonc/mdv221
[5]	Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER-2 status, and prognosis of patients with Luminal B breast cancer[J]. J Natl Cancer Inst, 2009, 101(10):736-750. doi: 10.1093/jnci/djp082
[6]	杨涛, 张朝蓬, 孙翔宇, 等.病理三维重建研究新辅助化疗后乳腺原发肿瘤的退缩模式[J].中华肿瘤杂志, 2016, 38(4):1-7. http://d.old.wanfangdata.com.cn/Periodical/zhzl201604008
[7]	Gentilini O, Intra M, Gandini S, et al. Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome[J]. J Surg Oncol, 2006, 94(5):375-379. doi: 10.1002/(ISSN)1096-9098
[8]	Curigliano G, Burstein HJ, Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017[J]. Ann Oncol, 2017, 28(8):1700-1712. doi: 10.1093/annonc/mdx308
[9]	Morrow M, Van Zee KJ, Solin LJ, et al. Society of surgical oncologyAmerican society for radiation oncology-American society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ[J]. Ann Surg Oncol, 2016, 23(12):3801-3810. doi: 10.1245/s10434-016-5449-z
[10]	Akay CL, Meric-Bernstam F, Hunt KK, et al. Evaluation of the MD Anderson prognostic index for local regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2012, 19 (3):901-907. doi: 10.1245/s10434-011-2006-7
[11]	Ballesio L, Gigli S, Di Pastena F, et al. Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvantchemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy[J]. Tumor Biology, 2017, 4(1):1-8. http://www.ncbi.nlm.nih.gov/pubmed/28347225
[12]	Fukada I, Araki K, Kobayashi K, et al. Pattern of tumor shrinkage during neoadjuvant chemotherapy is associated with prognosis in lowgrade Luminal early breast cancer[J]. Radiology, 2018, 286(1):49- 57. http://www.ncbi.nlm.nih.gov/pubmed/28737968
[13]	Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER-1, HER- 2, and response: a study of preoperative chemotherapy[J]. Ann Oncol, 2008, 19(3):465-472. http://www.ncbi.nlm.nih.gov/pubmed/17986623/
[14]	von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER-2 positive breast cancer[J]. N Engl J Med, 2017, 377(7):702. http://www.tandfonline.com/servlet/linkout?suffix=CIT0036&dbid=16&doi=10.1080%2F14737140.2018.1477596&key=10.1056%2FNEJMoa1703643